February 2018

SMA Newborn Screening Moves Forward in Indiana, Ohio and Georgia

The spinal muscular atrophy community is celebrating significant progress toward adding SMA to newborn screening panels in several states. Indiana Poised to Become the Fourth State to Adopt SMA Screening In Indiana, HB 1017 has been passed by both the House and Senate, and is currently awaiting Governor Eric Holcomb’s signature. This bill would institute […]

SMA Newborn Screening Moves Forward in Indiana, Ohio and Georgia Read More »

#ShowYourRare and Raise SMA Awareness on World Rare Disease Day

Rare Disease Day is today, February 28! And we’re calling on our entire spinal muscular atrophy community to get involved. Rare Disease Day is important to us because it is a time for individuals impacted by a rare disease—or those whose loved ones are impacted—to come together. It is a time for us to raise

#ShowYourRare and Raise SMA Awareness on World Rare Disease Day Read More »

Last Week’s Webinar on Treatment Access and Clinical Trials Now Available

A recording of last week’s webinar updating the community on treatment access and clinical trials is now available online. A PDF of the webinar presentation is also available for download. An update on the status of Spinraza dosing across the US included the following information: As of December 2017, nearly 2,000 US patients had been

Last Week’s Webinar on Treatment Access and Clinical Trials Now Available Read More »

Cure SMA Receives Generous Gift from the Weisman Family Foundations

The Weisman Family Foundations recently awarded $65,800 to Cure SMA, in order to further new scientific research, and to help provide access to treatments, clinical trials and care. Each year, a generous donation is made by the Weisman Family Foundations. Through contributions from their foundation and associated family foundations, the Weisman family has given over

Cure SMA Receives Generous Gift from the Weisman Family Foundations Read More »

Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018

Cytokinetics is currently conducting a Phase 2 clinical trial of CK-2127107 – now referred to by the generic name, reldesemtiv – which is designed to assess the investigational agent’s effect on multiple measures of muscle function in both ambulatory and non-ambulatory patients with SMA. The trial includes two cohorts of varying doses of reldesemtiv. Enrollment

Phase 2 Clinical Trial Results for CK-2127107 Expected in Second Quarter of 2018 Read More »

Biogen Releases Statement on CHERISH Data and Plans for New Clinical Research

Biogen has provided the following community statement on the final results from CHERISH, a Phase 3 study of SPINRAZA.  Dear Members of the SMA community, This past December marked one year since the FDA approval of SPINRAZA® (nusinersen), the first and only treatment option for children and adults living with SMA in the U.S. Since

Biogen Releases Statement on CHERISH Data and Plans for New Clinical Research Read More »

Additional Funding for SMA Care Centers Announced

Cure SMA is pleased to announce the second round of grants from $450,000 in funding, awarded to a total of 9 sites to help increase capacity at SMA treatment centers across the US. In January 2018, Cure SMA selected five additional treatment centers, totaling $200,000, to receive a grant to further increase the number of

Additional Funding for SMA Care Centers Announced Read More »

Cure SMA Announces Local Educational Symposiums in 16 US Locations

Cure SMA is pleased to announce a slate of one-day local symposiums, beginning late spring and continuing into fall 2018. The symposiums will be held in 16 locations across 15 states across the US. Through these local symposiums, the SMA community will continue to share experiences, advocate for one another, and learn about the latest

Cure SMA Announces Local Educational Symposiums in 16 US Locations Read More »

Winter 2018 Compass Now Available Online

The winter 2018 issue of Compass is now available online. This issue covers Cure SMA’s community survey, and reviews how data is used to improve research, care and coverage in the SMA community. Cure SMA Community Update Survey Cure SMA has been collecting data through our database and various projects over the past several years.

Winter 2018 Compass Now Available Online Read More »

Scroll to Top